S&P 500:  2,738.38  +12.16 (+0.45%)
DOW:  25,421.56  +34.38 (+0.14%)
NASDAQ:  7,251.00  +50.00 (+0.69%)

NASDAQ:CUE - Cue Biopharma News Headlines

Sign in or create an account to add this stock to your watchlist.
Get Started
$6.21 +0.09 (+1.47 %)
(As of 11/13/2018 12:42 PM ET)
Previous Close$6.12
Today's Range$6.10 - $6.62
52-Week Range$5.90 - $17.99
Volume39,179 shs
Average Volume109,151 shs
Market Capitalization$143.95 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Cue Biopharma (NASDAQ CUE) News Headlines

Source:
DateHeadline
Cue Biopharma Inc. (CUE) Presents Foundational Data on Immuno-STAT Platform and CUE-101 at SITCCue Biopharma Inc. (CUE) Presents Foundational Data on Immuno-STAT Platform and CUE-101 at SITC
www.streetinsider.com - November 9 at 10:57 AM
Cue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual MeetingCue Biopharma Presents Foundational Data on Immuno-STAT Platform and CUE-101 at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
finance.yahoo.com - November 9 at 10:57 AM
BRIEF-Cue Biopharma announces strategic collaboration with Lg Chem Life Sciences for Immuno-Stat biologics in oncologyBRIEF-Cue Biopharma announces strategic collaboration with Lg Chem Life Sciences for Immuno-Stat biologics in oncology
www.msn.com - November 8 at 10:43 AM
Cue Bio up 7% premarket on LG Chem partnershipCue Bio up 7% premarket on LG Chem partnership
seekingalpha.com - November 8 at 10:43 AM
Cue Biopharma Announces Strategic Collaboration with LG Chem Life Sciences for Immuno-STAT™ Biologics in OncologyCue Biopharma Announces Strategic Collaboration with LG Chem Life Sciences for Immuno-STAT™ Biologics in Oncology
finance.yahoo.com - November 8 at 10:43 AM
Cue Biopharma Announces Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual MeetingCue Biopharma Announces Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
finance.yahoo.com - October 30 at 10:33 AM
Cue Biopharma Announces Strategic Research Collaboration with Albert Einstein College of Medicine to Further the Potential of Immuno-STAT™ Platform in Chronic Infectious DiseasesCue Biopharma Announces Strategic Research Collaboration with Albert Einstein College of Medicine to Further the Potential of Immuno-STAT™ Platform in Chronic Infectious Diseases
finance.yahoo.com - October 17 at 10:15 AM
What Kind Of Shareholders Own Cue Biopharma Inc (NASDAQ:CUE)?What Kind Of Shareholders Own Cue Biopharma Inc (NASDAQ:CUE)?
finance.yahoo.com - October 16 at 3:29 PM
Form 4 Cue Biopharma, Inc. For: Aug 29 Filed by: Millar Kerri-AnnForm 4 Cue Biopharma, Inc. For: Aug 29 Filed by: Millar Kerri-Ann
www.streetinsider.com - August 30 at 10:45 AM
Cue Biopharma, Inc. (CUE) CEO Dan Passeri Hosts Investor Business Update Call (Transcript)Cue Biopharma, Inc. (CUE) CEO Dan Passeri Hosts Investor Business Update Call (Transcript)
seekingalpha.com - August 28 at 10:30 AM
Cue Biopharma Adds Frank Morich, M.D., Ph.D. to Board of DirectorsCue Biopharma Adds Frank Morich, M.D., Ph.D. to Board of Directors
finance.yahoo.com - August 3 at 11:41 AM
Cue Biopharma Appoints Bethany Mancilla as Chief Business Officer and Senior Vice PresidentCue Biopharma Appoints Bethany Mancilla as Chief Business Officer and Senior Vice President
finance.yahoo.com - July 24 at 10:35 AM
Cue Biopharma (CUE) Reports Progress in Ongoing Strategic Collaboration & License Agreement with Merck (MRK) to Develop Immuno-STATsCue Biopharma (CUE) Reports Progress in Ongoing Strategic Collaboration & License Agreement with Merck (MRK) to Develop Immuno-STATs
www.streetinsider.com - July 12 at 10:17 AM
Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with MerckCue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck
finance.yahoo.com - July 12 at 10:17 AM
Form 8-K Cue Biopharma, Inc. For: Jun 26Form 8-K Cue Biopharma, Inc. For: Jun 26
www.streetinsider.com - June 27 at 10:33 AM
Cue Biopharma to Host Investor Business Update Call and WebcastCue Biopharma to Host Investor Business Update Call and Webcast
finance.yahoo.com - May 10 at 8:49 AM
BRIEF-Cue Biopharma - On April 30,Gary Schuman Resigned As Interim CFOBRIEF-Cue Biopharma - On April 30,Gary Schuman Resigned As Interim CFO
www.reuters.com - May 1 at 8:45 AM
Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific OfficerCue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific Officer
finance.yahoo.com - April 25 at 8:33 AM
Cue Biopharma to Present at Bloomberg Biotech Innovations ConferenceCue Biopharma to Present at Bloomberg Biotech Innovations Conference
finance.yahoo.com - April 5 at 9:45 AM
BRIEF-Peter Appel Reports Passive Stake Of 7.6 Pct In Cue BiopharmaBRIEF-Peter Appel Reports Passive Stake Of 7.6 Pct In Cue Biopharma
www.reuters.com - February 14 at 8:01 AM
Cue Biopharma to Present at BIO CEO & Investor ConferenceCue Biopharma to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 10:00 AM
Cue Biopharma to Provide Corporate Update at the 10th Annual Biotech Showcase 2018 ConferenceCue Biopharma to Provide Corporate Update at the 10th Annual Biotech Showcase 2018 Conference
finance.yahoo.com - January 27 at 8:00 AM
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Featured Article: Stock Split
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel